From Cellular Origin to Clinical Recurrence: Rethinking Tumor Boundaries in Isocitrate Dehydrogenase-Mutant Gliomas
- 1Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul, Korea .
- 2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea .
Abstract
Isocitrate dehydrogenase (IDH)-mutant gliomas are primary malignant brain tumors that predominantly affect young adults, and are characterized by relatively favorable clinical outcomes compared with other brain malignancies. Despite advances in molecular classification and multimodal treatment, tumor recurrence remains inevitable in most patients, raising fundamental questions about the true extent of disease and the biological basis of recurrence. A recent study identified rare IDH1 mutation-bearing cells within histologically and radiologically normal peritumoral cortex, suggesting that the earliest stages of gliomagenesis may extend beyond the conventionally defined tumor margin. This observation suggests that these mutation-bearing cortical cells may contribute to tumor recurrence even after gross total resection and supports the potential value of early therapeutic intervention targeting these latent cells, such as with IDH inhibitors, to delay disease progression. Collectively, these insights suggest that IDH-mutant gliomas may be better understood as a spatially extended biological process rather than a strictly localized lesion. A more integrated approach that combines precise surgical techniques with molecularly informed therapies may improve long-term disease control.
Related
- Mutant Isocitrate Dehydrogenase 1 Alters Extracellular Vesicle Secretion and Cargo Composition in Cellular Models
- Imaging of Isocitrate Dehydrogenase-Mutant Gliomas in the Era of Isocitrate Dehydrogenase Inhibitors: What Radiologists Need to Know
- Enhancing 1p/19q Classification in Brain Gliomas Using Isocitrate Dehydrogenase Status: A Deep Learning Study
- Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology
- Discovery of Covalent Wild-Type Isocitrate Dehydrogenase 1 (IDH1) Inhibitors Targeting Cys269
BibTeX
@article{park2026from,
title = {{From Cellular Origin to Clinical Recurrence: Rethinking Tumor Boundaries in Isocitrate Dehydrogenase-Mutant Gliomas}},
author = {Jung Won Park},
journal = {Brain Tumor Research and Treatment},
year = {2026},
month = oct,
doi = {10.14791/btrt.2026.0018},
url = {https://doi.org/10.14791/btrt.2026.0018},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - From Cellular Origin to Clinical Recurrence: Rethinking Tumor Boundaries in Isocitrate Dehydrogenase-Mutant Gliomas
AU - Jung Won Park
PY - 2026
DA - 2026/10/22
JO - Brain Tumor Research and Treatment
DO - 10.14791/btrt.2026.0018
UR - https://doi.org/10.14791/btrt.2026.0018
AB - Isocitrate dehydrogenase (IDH)-mutant gliomas are primary malignant brain tumors that predominantly affect young adults, and are characterized by relatively favorable clinical outcomes compared with other brain malignancies. Despite advances in molecular classification and multimodal treatment, tumor recurrence remains inevitable in most patients, raising fundamental questions about the true extent of disease and the biological basis of recurrence. A recent study identified rare IDH1 mutation-bearing cells within histologically and radiologically normal peritumoral cortex, suggesting that the earliest stages of gliomagenesis may extend beyond the conventionally defined tumor margin. This observation suggests that these mutation-bearing cortical cells may contribute to tumor recurrence even after gross total resection and supports the potential value of early therapeutic intervention targeting these latent cells, such as with IDH inhibitors, to delay disease progression. Collectively, these insights suggest that IDH-mutant gliomas may be better understood as a spatially extended biological process rather than a strictly localized lesion. A more integrated approach that combines precise surgical techniques with molecularly informed therapies may improve long-term disease control.
SN - 2288-2405
SN - 2288-2413
ER -